Class summary at a glance.

Every drug in the Angiotensin II Receptor Blocker (ARB) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $542.3Mcombined across class
Total Rx claims: 55.1M17.3M unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Losartan

Brand: ARBLI · 55.1M Part D claims (CY24) · 17.3M beneficiaries · First FDA approval: 2010-10-04

17 generic mfrs 0 plans require PA

Low NADAC$0.021

→

Avg plan cost$0.230

Part D spend $542.3M 11× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Candesartan

— Part D claims (CY24) · First FDA approval: 2016-12-06

Brand-only (no generics) 0 plans require PA

Low NADAC$0.495

→

Avg plan cost$0.549

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.